Supernus Pharmaceuticals (SUPN) Net Equity Issued and Repurchased (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Net Equity Issued and Repurchased data on file, last reported at $13.7 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased rose 569.44% year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $49.2 million, a 250.74% increase from a year earlier, with the FY2025 full-year figure at $37.6 million, up 152.32% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $13.7 million, up from $8.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for SUPN reached as high as $23.7 million in Q3 2025 and fell as low as $740000.0 in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $5.0 million across 5 years, with a median of $2.8 million in 2022.
• Across the five-year window, Net Equity Issued and Repurchased jumped 1131.87% in 2022 and slumped 88.54% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $2.8 million in 2022, then sank by 61.4% to $1.1 million in 2023, then jumped by 529.76% to $6.9 million in 2024, then grew by 24.43% to $8.6 million in 2025, then surged by 59.75% to $13.7 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $13.7 million in Q1 2026, $8.6 million in Q4 2025, and $23.7 million in Q3 2025.